Medios AG records further revenue growth in the first quarter of 2024 and
confirms full-year guidance

EQS-News: Medios AG / Key word(s): Quarterly / Interim Statement/Quarter
Results
Medios AG records further revenue growth in the first quarter of 2024 and
confirms full-year guidance

07.05.2024 / 07:31 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press release

Medios AG records further revenue growth in the first quarter of 2024 and
confirms full-year guidance

* Revenue increases by 5.8% to EUR456.2 million in the first quarter

* Cash flow from operating activities increases to EUR43.4 million

* Closing of the Ceban acquisition planned for May 2024

  * Guidance 2024 confirmed: Significant increase in revenue and margin
    expected

Berlin, May 7, 2024 - Medios AG ('Medios'), the leading provider of
Specialty Pharma solutions in Germany, confirms its guidance for the 2024
financial year after a solid first quarter. Revenue increased by 5.8%
year-on-year to EUR456.2 million in the period from January to March 2024
(previous year: EUR431.2 million). At EUR15.1 million (previous year: EUR15.0
million), EBITDA pre1 reached the level of the same quarter of the previous
year. As a result, the EBITDA pre1 margin of 3.3% (previous year: 3.5%) was
slightly lower than in the same period of the previous year. Cash flow from
operating activities improved significantly in the first quarter of 2024 to
EUR43.4 million (previous year:
EUR-25.3 million).

Heterogeneous sales and earnings development in the operating segments

The Pharmaceutical Supply segment achieved an increase in revenue of 8.9% to
EUR401.0 million in the first quarter of 2024 (previous year: EUR368.1 million).
The segment's EBITDA pre1 increased by 9.0% to EUR11.0 million (previous year:
EUR10.1 million).

The Patient-Specific Therapies segment generated revenue of EUR55.1 million in
the first quarter of 2024 after EUR62.9 million in the previous year. Around
EUR3.5 million of this decline was attributable to the sale of Kölsche Blister
GmbH in June 2023. In addition, regulatory price adjustments in some
compounding areas still had a negative impact on the earnings development.
As a result, the segment's EBITDA pre1 decreased by 9.4% to EUR5.9 million
(previous year: EUR6.6 million).

Matthias Gaertner, Chief Executive Officer (CEO) of Medios AG: 'In the first
quarter of 2024, we once again achieved an increase in revenue and
significantly increased our cash flow - despite the focus on the acquisition
of Ceban, which we expect to successfully complete shortly. With an even
larger Medios Group, which will also operate internationally for the first
time, we expect to continue our successful growth trajectory for the rest of
the 2024 financial year.'

In the first quarter of 2024, Medios announced the acquisition of Ceban
Pharmaceuticals B.V. ('Ceban'). Ceban is the Dutch market leader in
pharmaceutical compounding services and is also active in Belgium and Spain.
In 2023, Ceban generated revenue of approximately EUR160 million and an
adjusted EBITDA of approximately EUR29 million, which corresponds to an
adjusted EBITDA margin of around 18%. The acquisition represents an
important step in Medios' growth strategy, which aims to build the leading
European Specialty Pharma platform.

Positive outlook

Medios confirms the guidance for the 2024 financial year first announced on
March 18, 2024. The company expects revenue of EUR1.9 billion to EUR2.1 billion
and EBITDA pre1 of EUR82 million to EUR91 million. This expectation is based on
the assumption that the acquisition of Ceban Pharmaceuticals B.V. will be
completed shortly and fully consolidated from the beginning of May 2024.

In the medium term, the market share in the area of patient-specific
therapies in particular is to be further expanded, thereby increasing the
profitability of the entire Medios Group. Accordingly, Medios is aiming for
consolidated revenue of more than EUR2bn and an EBITDA pre1 margin at least in
the mid-single-digit range in the medium term.

Key figures (IFRS)

  in EUR million                          Q1 2024      Q1 2023      in %
  Revenue                                 456.2        431.2        5.8
  Pharmaceutical Supply                   401.0        368.1        8.9
  Patient-Specific Therapies               55.1         62.9      -12.5
  Services                                  0.1          0.2      -23.3
  EBITDA pre1                              15.1         15.0        0,6
  Pharmaceutical Supply                    11.0         10.1        9.0
  Patient Specific Therapies                5.9          6.6       -9.4
  Services                                 -1.9         -1.7        9.8
  Cashflow from operating activities       43.4        -25.3    <-100.0

Important dates for Medios AG in the 2024 financial year

June 6 to 7: Warburg Highlights - Hamburg

August 13: Half-Year Financial Report 2024

August 14: Annual General Meeting 2024

September 25: Berenberg and Goldman Sachs 13th German Corporate

Conference - Munich

November 12: Quarterly statement as of September 30, 2024

Medios AG's quarterly statement as of March 31, 2024 is available for
download on the Investor Relations website.

1 EBITDA is defined as consolidated earnings before interest, taxes,
depreciation and amortization. EBITDA pre is adjusted for special charges
for stock options and expenses for M&A activities as well as for
performance-related payments for the acquisition of compounding volumes and,
from 2024, for expenses for the introduction of an ERP system.

-------------------

About Medios AG

Medios AG is the leading provider of Specialty Pharma Solutions in Germany.
As a competence partner and expert, Medios covers all relevant aspects of
the supply chain in this field: from pharmaceutical supply to the
manufacture of patient-specific therapies including blistering. The focus is
on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed specialty pharmaceutical company. The
shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the
Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

c.nickolaus@medios.ag

www.medios.ag

Disclaimer

This communication contains forward-looking statements that are subject to
certain risks and uncertainties. Future results could differ materially from
those currently anticipated as a result of various risk factors and
uncertainties, including, but not limited to, changes in business, economic
and competitive conditions, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings and the
availability of financing.


---------------------------------------------------------------------------

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Medios AG
                   Heidestraße 9
                   10557 Berlin
                   Germany
   Phone:          +49 30 232 566 - 800
   Fax:            +49 30 232 566 - 801
   E-mail:         ir@medios.ag
   Internet:       www.medios.ag
   ISIN:           DE000A1MMCC8
   WKN:            A1MMCC
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1896957

End of News EQS News Service
---------------------------------------------------------------------------

1896957 07.05.2024 CET/CEST